ArticleCancer science2021

Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.

Yunxiong Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.